Determining Treatment Duration for Transplant-Eligible NDMM

Final analysis data from the phase 3 ALCYONE trial support using frontline daratumumab-containing regimens for those with transplant-ineligible NDMM.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Subgroup data from the IMROZ trial showed Isa-VRd improved survival and responses vs VRd alone in patients who were frail with newly diagnosed myeloma.

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.